非酒精性脂肪性肝病及肝活检评估的持续作用。
Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.
作者信息
Brunt Elizabeth M
机构信息
Department of Pathology and Immunology Washington University School of Medicine St Louis MO.
出版信息
Hepatol Commun. 2017 Jun 7;1(5):370-378. doi: 10.1002/hep4.1055. eCollection 2017 Jul.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common underlying causes of chronically elevated liver tests and liver disease in adults and children worldwide and may be strongly suspected if not diagnosed by ever evolving and available serologic and imaging-based noninvasive tests. However, the definitive diagnosis of the most progressive form of NAFLD, nonalcoholic steatohepatitis, and the identification of fibrosis stage still require liver biopsy evaluation as noninvasive testing has not replaced some of the specifics or the totality of information obtainable from liver biopsy. In this review, both the role and value of a liver biopsy evaluation in NAFLD/ nonalcoholic steatohepatitis are examined from publications related to a selected variety of settings. Details of the most commonly used semiquantitative methods of analysis are discussed, and some useful potential pitfalls for differential diagnostic consideration in liver biopsy interpretation are given. ( 2017;1:370-378).
摘要
非酒精性脂肪性肝病（NAFLD）是全球成人和儿童慢性肝功能检查异常及肝病最常见的潜在病因之一。如果不断发展且可用的血清学和基于影像学的非侵入性检查未做出诊断，则强烈怀疑可能患有该病。然而，对于NAFLD最进展形式的非酒精性脂肪性肝炎的明确诊断以及纤维化阶段的确定，仍需要肝活检评估，因为非侵入性检查尚未取代从肝活检中可获得的一些具体信息或全部信息。在本综述中，从与选定的各种情况相关的出版物中，研究了肝活检评估在NAFLD/非酒精性脂肪性肝炎中的作用和价值。讨论了最常用的半定量分析方法的细节，并给出了肝活检解读中鉴别诊断需考虑的一些有用的潜在陷阱。（2017；1：370 - 378）
相似文献
1
Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.非酒精性脂肪性肝病及肝活检评估的持续作用。
Hepatol Commun. 2017 Jun 7;1(5):370-378. doi: 10.1002/hep4.1055. eCollection 2017 Jul.
2
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的组织病理学
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
3
Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.血清细胞角蛋白-18及其与非酒精性脂肪性肝病和丙型肝炎病毒患者通过FibroScan诊断的肝纤维化及受控衰减参数测定的肝脂肪变性的关系。
Eur J Gastroenterol Hepatol. 2019 May;31(5):633-641. doi: 10.1097/MEG.0000000000001385.
4
Diagnostic evaluation of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的诊断评估
J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S34-8. doi: 10.1097/01.mcg.0000168642.38945.f1.
5
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.非酒精性脂肪性肝病的无创评估：当前证据与实践
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307.
6
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.非酒精性脂肪性肝病的诊断：有创与无创诊断方法
Semin Liver Dis. 2008 Nov;28(4):386-95. doi: 10.1055/s-0028-1091983. Epub 2008 Oct 27.
7
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的诊断和评估，包括无创生物标志物和瞬时弹性成像。
Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.
8
Pathology of nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的病理学。
Hepatol Res. 2005 Oct;33(2):68-71. doi: 10.1016/j.hepres.2005.09.006. Epub 2005 Oct 7.
9
A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease.一种用于非酒精性脂肪性肝病谱系中确定性非酒精性脂肪性肝炎综合多模态无创诊断的贝叶斯方法。
Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1292-5. doi: 10.1097/MEG.0000000000000184.
10
Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.经活检证实的非酒精性脂肪性肝病患者血清可溶性凝集素样氧化型低密度脂蛋白受体-1水平升高。
World J Gastroenterol. 2015 Jul 14;21(26):8096-102. doi: 10.3748/wjg.v21.i26.8096.
引用本文的文献
1
The role of lipoprotein sulfatides in MASLD fibrosis transition: A new frontier in hepatic immunomodulation.脂蛋白硫脂在代谢相关脂肪性肝病纤维化转变中的作用：肝脏免疫调节的新前沿。
Metabol Open. 2024 Nov 28;25:100335. doi: 10.1016/j.metop.2024.100335. eCollection 2025 Mar.
2
The evolving role of liver biopsy: Current applications and future prospects.肝活检不断演变的作用：当前应用与未来前景。
Hepatol Commun. 2025 Jan 7;9(1). doi: 10.1097/HC9.0000000000000628. eCollection 2025 Jan 1.
3
Gallstones increase the risk of nonalcoholic fatty liver: A case-control study.胆结石增加非酒精性脂肪肝风险：一项病例对照研究。
Health Sci Rep. 2024 Nov 5;7(11):e70068. doi: 10.1002/hsr2.70068. eCollection 2024 Nov.
4
Hepatic SPARC Expression Is Associated with Inflammasome Activation during the Progression of Non-Alcoholic Fatty Liver Disease in Both Mice and Morbidly Obese Patients.肝组织中富含半胱氨酸的酸性分泌蛋白表达与非酒精性脂肪性肝病进展过程中的炎症小体激活相关，这种现象在肥胖症患者和实验鼠中均有体现。
Int J Mol Sci. 2023 Oct 2;24(19):14843. doi: 10.3390/ijms241914843.
5
Effect of Hepatic Pathology on Liver Regeneration: The Main Metabolic Mechanisms Causing Impaired Hepatic Regeneration.肝病理学对肝脏再生的影响：导致肝脏再生受损的主要代谢机制。
Int J Mol Sci. 2023 May 23;24(11):9112. doi: 10.3390/ijms24119112.
6
The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases.非侵入性评分在血清转氨酶正常和升高的非酒精性脂肪性肝病患者中的应用。
Hepatol Forum. 2020 Jan 20;1(1):8-13. doi: 10.14744/hf.2020.0006. eCollection 2020 Jan.
7
MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.用于肝脂肪变性、非酒精性脂肪性肝炎和肝纤维化诊断的MAFLD/NAFLD无创评分系统
Front Med (Lausanne). 2022 Jan 13;8:774079. doi: 10.3389/fmed.2021.774079. eCollection 2021.
8
High frequency and long persistency of ballooning hepatocyte were associated with glucose intolerance in patients with severe obesity.高频且持久的气球样肝细胞与严重肥胖患者的葡萄糖不耐受有关。
Sci Rep. 2021 Jul 28;11(1):15392. doi: 10.1038/s41598-021-94937-4.
9
Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents.富含生育三烯酚的维生素E组分对肥胖儿童和青少年非酒精性脂肪性肝病可能的肝保护作用。
Front Pediatr. 2021 Jul 8;9:667247. doi: 10.3389/fped.2021.667247. eCollection 2021.
10
Modeling alcohol-associated liver disease in a human Liver-Chip.在人肝芯片中模拟酒精性肝病。
Cell Rep. 2021 Jul 20;36(3):109393. doi: 10.1016/j.celrep.2021.109393.
本文引用的文献
1
In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis.在非酒精性脂肪性肝病患儿中，1 区脂肪变性与晚期纤维化相关。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):438-446.e1. doi: 10.1016/j.cgh.2017.02.030. Epub 2017 Mar 7.
2
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions.AISF关于非酒精性脂肪性肝病（NAFLD）的立场文件：更新与未来方向
Dig Liver Dis. 2017 May;49(5):471-483. doi: 10.1016/j.dld.2017.01.147. Epub 2017 Jan 23.
3
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.非酒精性脂肪性肝病中纤维化阶段导致的死亡风险增加：系统评价与荟萃分析
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
4
NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).NASPGHAN儿童非酒精性脂肪性肝病诊断与治疗临床实践指南：非酒精性脂肪性肝病专家委员会（ECON）及北美儿科胃肠病学、肝病学和营养学会（NASPGHAN）的建议
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334. doi: 10.1097/MPG.0000000000001482.
5
In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.在患有非酒精性脂肪性肝病的儿童中，酒石酸半胱胺缓释剂可改善肝酶，但不会降低疾病活动评分。
Gastroenterology. 2016 Dec;151(6):1141-1154.e9. doi: 10.1053/j.gastro.2016.08.027. Epub 2016 Aug 26.
6
Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.合并脂肪肝会增加慢性乙型肝炎患者患肝细胞癌的风险。
J Gastroenterol Hepatol. 2017 Mar;32(3):667-676. doi: 10.1111/jgh.13536.
7
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.非肥胖患者非酒精性脂肪性肝病的组织学严重程度与临床结局。
Hepatology. 2017 Jan;65(1):54-64. doi: 10.1002/hep.28697. Epub 2016 Jul 25.
8
Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.自身免疫性肝炎合并非酒精性脂肪性肝病患者的自然病史。
Dig Dis Sci. 2016 Sep;61(9):2710-20. doi: 10.1007/s10620-016-4213-3. Epub 2016 Jun 4.
9
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.丙型肝炎病毒感染中的非酒精性脂肪性肝病和非酒精性脂肪性肝炎：在肝脏和肝外表现中的患病率及意义
Int J Mol Sci. 2016 May 25;17(6):803. doi: 10.3390/ijms17060803.
10
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.
Zotero 插件